The systematic review by Ackermann et al1 of 45 controlled clinical trials on cardiovascular end points with garlic supplements represents an exhaustive and careful undertaking that has revealed problems in the design and blinding of many of the trials as well as the inconsistent or unknown quality of many of the products used in the trials. I am in agreement with all of the conclusions and criticisms expressed in the report, with one exception.